<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04510415</url>
  </required_header>
  <id_info>
    <org_study_id>HM-EMSI-103</org_study_id>
    <nct_id>NCT04510415</nct_id>
  </id_info>
  <brief_title>Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI</brief_title>
  <official_title>A Single-arm, Open-label, Phase 1b Study Evaluating the Efficacy and Safety of Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanmi Pharmaceutical Company Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanmi Pharmaceutical Company Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of olmutinib 600 mg QD in&#xD;
      patients with T790M-positive non-small cell lung cancer (NSCLC) after treatment with an&#xD;
      epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single-arm, open-label, Phase 1b study to evaluate the efficacy and safety of oral&#xD;
      single agent olmutinib administered to patients with T790M-positive NSCLC after treatment&#xD;
      with an EGFR-TKI.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study termination by the Sponsor&#xD;
  </why_stopped>
  <start_date type="Actual">March 29, 2018</start_date>
  <completion_date type="Actual">December 11, 2018</completion_date>
  <primary_completion_date type="Actual">December 11, 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as a best overall confirmed response of either CR or PR according to the RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the proportion of patients with a documented CR, PR, and SD during the treatment cycles according to the RECIST version 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall tumor response (DR)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the interval between the date of the first observation of tumor response (CR or PR) and the date of disease progression or death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1 or death due to any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>24 months</time_frame>
    <description>Defined as the time from first administration of study drug to determination of tumor progression by RECIST version 1.1</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">2</enrollment>
  <condition>Non Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Olmutinib 600mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HM61713 600 mg (1 x 400 mg + 1 x 200 mg tablets) once daily (QD)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmutinib</intervention_name>
    <description>600 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator&quot;s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.</description>
    <arm_group_label>Olmutinib 600mg</arm_group_label>
    <other_name>HM61713</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provide written informed consent before any study-specific procedures (including&#xD;
             special Screening tests) are performed.&#xD;
&#xD;
          -  At least 20 years of age at the time of signing informed consent.&#xD;
&#xD;
          -  Cytologically or histologically confirmed adenocarcinoma of locally advanced or&#xD;
             metastatic NSCLC which is not amenable to curative surgery or radiotherapy.&#xD;
&#xD;
          -  Radiologically confirmed disease progression after at least one line of treatment with&#xD;
             an EGFR-TKI with or without at least one line of chemotherapy.&#xD;
&#xD;
          -  At least one documented EGFR mutation which is known to be related with susceptibility&#xD;
             to EGFR-TKIs (including G719X, exon 19 deletion, L858R, and L861Q).&#xD;
&#xD;
          -  World Health Organization (WHO) performance score of 0 to 1 with life expectancy of at&#xD;
             least 3 months.&#xD;
&#xD;
          -  Centrally confirmed T790M mutation positive tumor status from a tumor sample taken&#xD;
             after confirmation of disease progression on the most recent anticancer treatment&#xD;
             regimen.&#xD;
&#xD;
          -  At least one lesion (excluding the brain), not previously irradiated that can be&#xD;
             accurately measured per Response Evaluation Criteria in Solid Tumors (RECIST) version&#xD;
             1.1.&#xD;
&#xD;
          -  Females of child-bearing potential (not surgically sterilized and between menarche and&#xD;
             one-year post-menopause) must agree to use adequate contraception (one of the&#xD;
             following listed below) during the study (both men and women as appropriate) and for 3&#xD;
             months after the last dose of study drug.&#xD;
&#xD;
          -  Male patients should be documented to be sterile or agree to use barrier contraception&#xD;
             i.e. condoms.&#xD;
&#xD;
          -  Recovery to ≤ Grade 1 or baseline of any toxicities due to prior treatments, except&#xD;
             for stable sensory neuropathy ≤ Grade 2 and alopecia.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known history of hypersensitivity to active or inactive excipients of HM61713 or drugs&#xD;
             with a similar chemical structure of HM61713&#xD;
&#xD;
          -  Previous treatment with anticancer therapies, EGFR-TKI (including erlotinib,&#xD;
             gefitinib, and afatinib) within 8 days or 5-fold half-life, whichever is the longer,&#xD;
             of the first administration of study drug.&#xD;
&#xD;
          -  Any non-study related significant surgical procedures within the past 28 days prior to&#xD;
             the first administration of study drug&#xD;
&#xD;
          -  Spinal cord compression, leptomeningeal carcinomatosis or active symptomatic brain&#xD;
             metastases&#xD;
&#xD;
          -  History of any other malignancy&#xD;
&#xD;
          -  Clinically significant uncontrolled condition(s)&#xD;
&#xD;
          -  Active or chronic pancreatitis&#xD;
&#xD;
          -  Anyone with cardiac abnormalities or history&#xD;
&#xD;
          -  Presence or history of interstitial lung disease (ILD), drug-induced ILD, or presence&#xD;
             of radiation pneumonitis.&#xD;
&#xD;
          -  Pregnant or breast feeding.&#xD;
&#xD;
          -  In the opinion of the investigator, the patient is an unsuitable candidate to receive&#xD;
             HM61713.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hanmi Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Hanmi Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Bucheon St.Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea St.Vincent's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Uijeongbu St.Mary's Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Incheon St.Mary's Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic Univ. of Korea Seoul St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>August 7, 2020</study_first_submitted>
  <study_first_submitted_qc>August 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>August 11, 2020</last_update_submitted>
  <last_update_submitted_qc>August 11, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

